Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609566 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
A Phase 2 study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT04609566 is a Phase 2 study that has completed, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 161 participants.
The verdict
NCT04609566, a Phase 2 study, has completed, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Interventions
- DRUG pembrolizumab
- DRUG brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2026-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04609566
The ClinicalTrials.gov registry entry for NCT04609566 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04609566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04609566 about?
NCT04609566 is a clinical study titled "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors". This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side ...
What is the current status of trial NCT04609566?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2021-01-26. Estimated completion is 2026-02-03.
What interventions are being tested in trial NCT04609566?
The interventions under investigation include: pembrolizumab (DRUG), brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT04609566?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.